Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H29N5O3 |
Molecular Weight | 435.5197 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(=O)N(Cc1ccc(cc1)-c2ccccc2-c3n[nH]nn3)[C@@]([H])(C(C)C)C(=O)O
InChI
InChIKey=ACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
Molecular Formula | C24H29N5O3 |
Molecular Weight | 435.5197 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/25052956Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/2009869
Sources: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021283s50lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/25052956
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/2009869
There is no information in the literature about pharmacological and biological application of definite isomer of valsatran, R – form (also known as VALSARTAN, D- or CGP-49309). However there were found, that in the tablets of valsartan, which are used to treat high blood pressure and to heart failure, the R-enantiomer was an impurity.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26663387https://www.ncbi.nlm.nih.gov/pubmed/23227311
Curator's Comment:: LBQ657 (an LCZ696 metabolite) achieves CSF concentrations sufficient to inhibit neprilysin, but LCZ696 did not cause changes in CSF levels of aggregable Abeta isoforms (1-42 and 1-40) compared with placebo
Originator
Sources: https://www.novartis.com/news/media-releases/novartis-new-heart-failure-medicine-lcz696-now-called-entrestotm-approved-fdahttps://www.ncbi.nlm.nih.gov/pubmed/8505092
Curator's Comment:: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL227 |
2.38 nM [Ki] | ||
Target ID: CHEMBL1944 |
2.3 nM [IC50] | ||
Target ID: CHEMBL227 |
2.43 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ENTRESTO Approved UseENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB. Launch Date1.43614083E12 |
|||
Primary | DIOVAN Approved UseDiovan is an angiotensin II receptor blocker (ARB) indicated for:
Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1)
Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2)
Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date1.31086077E12 |
|||
Primary | DIOVAN Approved UseDiovan is an angiotensin II receptor blocker (ARB) indicated for:
Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1)
Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2)
Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date1.31086077E12 |
|||
Palliative | DIOVAN Approved UseDiovan is an angiotensin II receptor blocker (ARB) indicated for:
Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1)
Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2)
Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) Launch Date1.31086077E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2808 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5756 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.141 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20650 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
34310 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22.56 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27128457 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.55 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21617777 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
VALSARTAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2.24 mg single, oral Overdose |
unknown, 25 years n = 1 Health Status: unknown Age Group: 25 years Sex: F Population Size: 1 Sources: |
Other AEs: Muscle cramps... |
640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Disc. AE: Hyperkalemia... Other AEs: Dizziness, Headache... AEs leading to discontinuation/dose reduction: Hyperkalemia (1 patient) Other AEs:Dizziness (8.3%) Sources: Headache (9.2%) Back pain (5.8%) Upper respiratory tract infection (5.8%) Nasopharyngitis (5%) Diarrhea (5%) Hypoglycemia (5%) Peripheral edema (4.2%) Nausea (4.2%) |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
pregnant Health Status: pregnant Sources: |
Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: |
Disc. AE: Headache, Dizziness... AEs leading to discontinuation/dose reduction: Headache (2.3%) Sources: Dizziness (2.3%) |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: |
Disc. AE: Creatinine increased, Potassium increased... AEs leading to discontinuation/dose reduction: Creatinine increased (0.5%) Sources: Potassium increased (0.5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Muscle cramps | 1 patient | 2.24 mg single, oral Overdose |
unknown, 25 years n = 1 Health Status: unknown Age Group: 25 years Sex: F Population Size: 1 Sources: |
Hyperkalemia | 1 patient Disc. AE |
640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Nausea | 4.2% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Peripheral edema | 4.2% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Diarrhea | 5% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Hypoglycemia | 5% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Nasopharyngitis | 5% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Back pain | 5.8% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Upper respiratory tract infection | 5.8% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Dizziness | 8.3% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Headache | 9.2% | 640 mg 1 times / day steady, oral Highest studied dose Dose: 640 mg, 1 times / day Route: oral Route: steady Dose: 640 mg, 1 times / day Sources: |
unhealthy, 57.5 years n = 131 Health Status: unhealthy Age Group: 57.5 years Sex: M+F Population Size: 131 Sources: |
Disorder fetal | Disc. AE | 320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
pregnant Health Status: pregnant Sources: |
Dizziness | 2.3% Disc. AE |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: |
Headache | 2.3% Disc. AE |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2316 Health Status: unhealthy Condition: hypertension Population Size: 2316 Sources: |
Creatinine increased | 0.5% Disc. AE |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: |
Potassium increased | 0.5% Disc. AE |
320 mg 1 times / day steady, oral Recommended Dose: 320 mg, 1 times / day Route: oral Route: steady Dose: 320 mg, 1 times / day Sources: |
unhealthy n = 2506 Health Status: unhealthy Condition: Heart Failure Population Size: 2506 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. | 1993 Oct |
|
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. | 1994 |
|
Binding of valsartan to mammalian angiotensin AT1 receptors. | 1995 Nov 10 |
|
Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. | 1996 Jun-Jul |
|
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester. | 1996 Nov 8 |
|
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. | 1996 Sep |
|
Enantiomeric LC separation of valsartan on amylose based stationary phase. | 2009 Aug |
|
Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. | 2014 Apr |
|
Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis. | 2015 |
|
LCZ696 : a new paradigm for the treatment of heart failure? | 2015 Feb |
|
Sacubitril/valsartan (LCZ696) for the treatment of heart failure. | 2016 |
|
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. | 2016 Apr |
|
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. | 2016 Aug |
|
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. | 2016 Jan |
|
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. | 2016 Mar |
Sample Use Guides
The recommended starting dose of ENTRESTO, previously known as LCZ696, is 49/51 mg (sacubitril/valsartan) twice-daily. Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
Route of Administration:
Oral
In Vitro Use Guide
Sources: Von Lueder TG, Wang B, Kompa A, Huang L, Webb R, Jordan P, Krum H. ARNi, combined neprilysin and angiotensin receptor inhibition augments anti-fibrotic and anti-hypertrophic effects in vitro. Eur.Heart J. 2012;33:P5834.
Curator's Comment:: ...
30 nM to 1 uM valsartan (LCZ696 component) in the presence of 10 uM LBQ657 (Sacubitril (LCZ696 component) metabolite) demonstrate anti-fibrotic and anti-hypertrophic effects on rat cardiac fibroblasts and cardiomyocytes, respectively, cultured with 100 nM angiotensin II
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:02:21 UTC 2021
by
admin
on
Fri Jun 25 21:02:21 UTC 2021
|
Record UNII |
80M03YXJ7I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C09CA03
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
IMPRADA-HCT (WITHDRAWN: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C10BX10
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
EXFORGE (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-VATC |
QC09CA03
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
NDF-RT |
N0000175561
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DX02
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
COPALIA (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DX01
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-VATC |
QC09DA03
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
EXFORGE-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
NCI_THESAURUS |
C66930
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DB08
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DARFIRO-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
LIVERTOX |
1019
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
COPALIA-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DA03
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
NDF-RT |
N0000000070
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
DAFIRO (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
FDA ORPHAN DRUG |
494115
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-VATC |
QC09DX01
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
IMPRIDA (AUTHORIZED: HYPERTENSION)
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DX05
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DX04
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-VATC |
QC09DX02
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-ATC |
C09DB01
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
||
|
WHO-VATC |
QC09DB01
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7016
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
69749
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | RxNorm | ||
|
137862-53-4
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
3937
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
CHEMBL1069
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
80M03YXJ7I
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
C081489
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
VALSARTAN
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
1708762
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | USP-RS | ||
|
7519
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
137862-53-4
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
DB00177
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
C47781
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
Valsartan
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
2806
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
M11372
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | Merck Index | ||
|
60846
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY | |||
|
SUB00017MIG
Created by
admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
Valsartan was metabolized to a small extent only. The only notable metabolite in plasma, urine and faecs
MAJOR
FECAL; PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Probable human carcinogen.
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Priority toxic pollutant.
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
NDMA is an organic chemical that is in a family of potent carcinogens.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Route of Elimination | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
PROTEIN BINDING | PHARMACOKINETIC |
|
|
|||
Route of Elimination | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
RENAL CLEARANCE | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||